Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 27, 2015 1:59 PM ET

Biotechnology

Company Overview of Neostem, Inc.

Executive Profile

Hans S. Keirstead Ph.D.

President of NeoStem Oncology, Neostem, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 7 different industries.

See Board Relationships
----

Background

Dr. Hans S. Keirstead, PhD serves as the President of NeoStem Oncology at Neostem, Inc. Dr. Keirstead serves as Chief Executive Officer and President at California Stem Cell, Inc. Dr. Keirstead founded Ability Biomedical Corporation and serves as its President and Chief Executive Officer. Dr. Keirstead served as Chief Executive Officer of Neuron Therapeutics, Inc. since 2000 and was responsible for developing its IND application and clinical trials program. He maintains ...

Corporate Headquarters

420 Lexington Avenue
New York, New York 10170

United States

Phone: 212-584-4180
Fax: 646-514-7787

Board Members Memberships

President, Chief Executive Officer, and Director
2014-Present
Director

Education

Doctorate
University of Cambridge
PhD
University Of British Columbia

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Executive Officer
Athersys, Inc.
$599.8K
Robin C. Stracey Interim Chief Executive Officer and Director
Cesca Therapeutics Inc.
--
Marc H. Hedrick M.D.Chief Executive Officer, President, Director and Member of Executive Committee
Cytori Therapeutics, Inc.
$437.4K
Martin M. McGlynn Chief Executive Officer, Director, Member of Strategic Transactions Committee, Chief Executive Officer of Stemcells California Inc and President of Stemcells California Inc
StemCells Inc.
$789.5K
Martin P. Rosendale Chief Executive Officer and Director
Nuo Therapeutics, Inc.
$385.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neostem, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.